Abstract
Forty-eight-week results from a randomized, multicentre, part-blinded, phase IIb clinical trial assessing the efficacy and safety of 400 and 800 mg etravirine twice daily (phase IIb formulation) and optimized background regimen versus standard-of-care regimen are presented. Both etravirine doses demonstrated sustained virological suppression at 48 weeks and a favourable tolerability profile. Etravirine demonstrated higher efficacy than control, irrespective of the number of detectable nonnucleoside reverse transcriptase inhibitor-resistance-associated mutations at baseline or active background antiretrovirals.
Publication types
-
Clinical Trial, Phase II
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-HIV Agents / administration & dosage*
-
Anti-HIV Agents / adverse effects
-
Anti-HIV Agents / therapeutic use
-
Dose-Response Relationship, Drug
-
HIV Infections / drug therapy*
-
HIV Infections / virology
-
HIV-1 / isolation & purification*
-
Humans
-
Nitriles
-
Pyridazines / administration & dosage*
-
Pyridazines / adverse effects
-
Pyridazines / therapeutic use
-
Pyrimidines
-
Single-Blind Method
-
Treatment Outcome
-
Viral Load
Substances
-
Anti-HIV Agents
-
Nitriles
-
Pyridazines
-
Pyrimidines
-
etravirine